Estrogen receptor-positive (ER+) breast cancer is the most frequent breast cancer subtype. Agents targeting the ER signaling pathway have been successful in reducing mortality from breast cancer for decades. However, mechanisms of resistance to these treatments arise, especially in the metastatic setting. Recently, it has been recognized that epigenetic dysregulation is a common feature that facilitates the acquisition of cancer hallmarks across cancer types, including ER+ breast cancer. Alterations in epigenetic regulators and transcription factors (TF) coupled with changes to the chromatin landscape have been found to orchestrate breast oncogenesis, metastasis, and the development of a resistant phenotype. Here, we review recent advances in our understanding of how the epigenome dictates breast cancer tumorigenesis and resistance to targeted therapies and discuss novel therapeutic interventions for overcoming resistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbcan.2024.189097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A study on the pharmacovigilance of various SGLT-2 inhibitors.
Front Med (Lausanne)
January 2025
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Sodium-glucose co-transporter two inhibitors (SGLT2is) are widely used in clinical practice due to their proven cardiovascular and renal benefits. However, various adverse drug reactions (ADRs) have been reported. This study aims to systematically update the ADRs associated with SGLT2is and identify the differences among various SGLT2is acovigilance of various SGLT-2 inhibitors.
View Article and Find Full Text PDFMalignant breast adenomyoepithelioma: case report and literature review.
Front Med (Lausanne)
January 2025
Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Malignant adenomyoepithelioma (MAME) of the breast is a rare tumor with both benign and malignant features. We report a case of a 67-year-old woman who presented with a mass in the outer quadrant of the right breast, detected during a routine check-up. The mass was classified as BI-RADS 3.
View Article and Find Full Text PDFGut microbiota, metabolites, and cytokines in relation to the risk of prostate cancer in the Asian population.
Front Oncol
January 2025
Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Purpose: Studies have shown that gut microbiota is involved in the tumorigenesis and development of prostate cancer. We aimed to perform a comprehensive analysis of causal associations of gut microbiota, metabolites, and cytokines with prostate cancer in the Asian population.
Patients And Methods: Genome-wide association study (GWAS) summary datasets were collected from the public databases.
Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus.
Front Oncol
January 2025
Department of Oncology, Tawam Hospital, Al Ain, United Arab Emirates.
Breast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancer-related mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for patients in metastatic settings. The recognition of "HER2-low" expression as a targetable category has caused a paradigm shift in the management of breast cancer.
View Article and Find Full Text PDFAdipokines in Breast Cancer: Decoding Genetic and Proteomic Mechanisms Underlying Migration, Invasion, and Proliferation.
Breast Cancer (Dove Med Press)
January 2025
Clinic for Plastic, Aesthetic and Reconstructive Surgery, Spine, Orthopedic and Hand Surgery, Preventive Medicine - ETHIANUM, Heidelberg, 69115, Germany.
Background: Adipokines, bioactive peptides secreted by adipose tissue, appear to contribute to breast cancer development and progression. While numerous studies suggest their role in promoting tumor growth, the exact mechanisms of their involvement are not yet completely understood.
Methods: In this project, varying concentrations of recombinant human adipokines (Leptin, Lipocalin-2, PAI-1, and Resistin) were used to study their effects on four selected breast cancer cell lines (EVSA-T, MCF-7, MDA-MB-231, and SK-Br-3).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!